Business Context and Reporting Period
This Form 8-K, dated June 30, 2006, reports a reverse merger between Gilder Enterprises, Inc. (a shell company) and MedaSorb Corporation (a medical device developer). Following the merger, Gilder Enterprises is now a development-stage company focused on blood purification technology. The filing also details a concurrent private placement of securities and the termination of Gilder's previous joint venture in internet connectivity.
Key Financial Metrics
- Revenue: The company has generated no revenues to date.
- Accumulated Deficit: As of March 31, 2006, MedaSorb reported an accumulated deficit of approximately $59.99 million.
- Operating Losses: Losses from operations were $3.67 million for the year ended December 31, 2005, and $1.02 million for the three months ended March 31, 2006.
- Cash Position: As of December 31, 2005, cash was approximately $707,000. Following the merger and private placement, the company received net proceeds of approximately $4.5 million.
- Liquidity: The $4.5 million in net proceeds is expected to fund operations for approximately 15 months. The auditors have expressed substantial doubt about the company's ability to continue as a going concern without additional financing.
- Debt: The company has a $1,000,000 advance from Margie Chassman bearing 6% interest, convertible into securities or repayable under specific conditions.
Material Changes
- Reverse Merger: Gilder Enterprises acquired MedaSorb Corporation. For accounting purposes, MedaSorb is treated as the acquirer, and its historical financial statements are now the company's historical statements.
- Capital Structure: The company issued 20,340,929 shares of Common Stock to former MedaSorb stockholders. Additionally, 5,250,000 shares of Series A 10% Cumulative Convertible Preferred Stock were sold to institutional investors for $5.25 million gross proceeds.
- Management Change: The former sole director and officer of Gilder Enterprises resigned. New leadership includes Al Kraus (CEO), James Winchester (CMO), Vincent Capponi (COO), and David Lamadrid (CFO).
- Asset Disposition: The company terminated its joint venture with 5G Wireless and sold its 51% interest in Nex Connectivity Solutions for $18,000 CAD, exiting the internet access business.
Guidance, Outlook, and Risks
- Product Strategy: The company is prioritizing the commercialization of CytoSorb (for sepsis and critical care) over BetaSorb (for chronic kidney failure) due to a faster regulatory pathway and higher potential margins.
- Regulatory Timeline: Management anticipates FDA approval for CytoSorb in 25 to 36 months, contingent on funding and successful clinical trials. A pilot study for sepsis is planned for the next 12 months.
- Capital Needs: The company expects to require additional financing after the 15-month runway provided by the recent private placement. There is no assurance that future capital will be available.
- Legal Risks: The company faces litigation from Purolite regarding patent ownership and potential disputes with Dow Chemical. There is also a pending claim from a former employee.
- Preferred Stock Terms: The Series A Preferred Stock includes a "full-ratchet" anti-dilution provision and a dividend rate that increases to 20% upon an event of default (e.g., failure to register shares within 240 days).
Investor Verification Checklist
- Verify the status of the Purolite litigation and the potential impact on patent ownership.
- Confirm the timeline and budget for the upcoming sepsis pilot study and pivotal trial.
- Review the terms of the Series A Preferred Stock, specifically the "full-ratchet" anti-dilution and default dividend provisions.
- Assess the company's ability to raise additional capital within the next 15 months to avoid insolvency.
- Monitor the progress of the registration statement required for the conversion of Preferred Stock and exercise of warrants (due within 240 days).